To evaluate the efficacy of combined JAK1/2 inhibition and TNFα antagonism in pediatric patients with severe steroid-resistant graft-versus-host disease (SR-GvHD), highlighting the significance of this approach in the context of existing treatments.
Approach:
Key Findings:
71.4% overall response rate (ORR) at day 28 for grade III–IV SR-aGvHD, with implications for treatment strategies. 75.0% of patients with SR-aGvHD maintained durable responses. 77.8% ORR at day 28 for SR-cGvHD, with 33.3% achieving durable responses. Overall survival of patients with SR-GvHD was 73.0% with a 59.5% GvHD-free survival at 40 months follow-up.
Interpretation:
The combination of JAK and TNFα inhibition led to meaningful clinical responses in over 70% of patients with severe SR-GvHD, suggesting potential for further investigation into mechanisms and treatment optimization.
Limitations:
Retrospective, observational nature of the study introduces potential biases. Low absolute numbers of pediatric patients with SR-GvHD limit prospective trial feasibility.
Conclusion:
The study supports further exploration of combined JAK- and TNFα-targeting strategies in treating severe SR-GvHD, emphasizing the need for prospective studies to validate these findings.
